Pilot Trial of the Move Healthier Group

September 15, 2026 updated by: Elizabeth.W.Lampe, Dartmouth-Hitchcock Medical Center
The researchers are developing a new exercise-focused group and are interested in studying whether this group helps people increase their exercise without increasing risk for disordered eating behaviors.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Individuals seeking weight loss are often encouraged to increase their exercise engagement as a health-promoting behavior. However, exercise engagement is often connected directly to caloric intake within weight loss interventions, so it is likely that individuals seeking weight loss are engaging in some level of compensatory exercise even in the absence of other disordered eating symptoms. Compensatory exercise is defined as exercising to "offset" or "make up for" calories consumed with the intent of controlling one's body weight or shape. The researchers are developing a new group to promote healthy exercise and are interested in studying whether this group helps people increase their exercise without increasing risk for compensatory exercise or other disordered eating behaviors.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
10

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • United States
    • New Hampshire
      • Lebanon, New Hampshire, United States, 03766
        • Dartmouth-Hitchcock Clinics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Seen for weight loss treatment at DHMC Weight Center within the past year
  • Speak, read, & write English fluently
  • Age 18 or older
  • Appropriate for group visits (as assessed by referring provider)

Exclusion Criteria:

  • Meets DSM-5 criteria for an eating disorder based on behavior frequencies reported on baseline EDE-Q
  • Report contraindications for unsupervised physical activity on the PAR-Q, or have not been medically cleared by an MD for participation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Move Healthier Group Intervention Arm
This group-based intervention aims to promote healthy exercise without increasing risk for compensatory exercise or other disordered eating behaviors. Participants will attend 8 weekly 90-minute group intervention sessions via telehealth software.
Behavioral: Move Healthier Intervention
The intervention aims to increase exercise using cognitive and behavioral skills integrated across several treatment manuals including the Physical Activity Cognitively Enhanced (PACE) intervention for healthy exercise promotion in eating disorders, acceptance-based and standard behavioral weight loss manuals, and affect-guided exercise prescriptions.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Objective physical activity
Time Frame: From enrollment to the end of treatment at 12 weeks
Objective physical activity will be measures as the total number of minutes per week of physical activity measured via Fitbit device worn during waking hours. The Fitbit data will yield a total count of the number of minutes of moderate-to-vigorous physical activity for each week during the intervention period, with higher counts indicating greater levels of activity.
From enrollment to the end of treatment at 12 weeks
Self-reported physical activity
Time Frame: From enrollment to the end of treatment at 12 weeks
Participants will also complete self-report measures of physical activity, including the International Physical Activity Questionnaire (IPAQ) and IPAQ-short form at group sessions and study assessments. The IPAQ asks patients to report on their total physical activity engagement over the past 7 days by light, moderate, and vigorous activity categories. The IPAQ yields a total count of the number of minutes of moderate-to-vigorous physical activity over the past week, with higher minutes indicating more activity.
From enrollment to the end of treatment at 12 weeks
Eating disorder symptoms
Time Frame: Baseline and post-intervention (week 12)
ED symptoms will be assessed via the Eating Disorder Examination Questionnaire (EDE-Q 6.0), which asks about ED symptoms over the past month (28 days). Compensatory exercise engagement will be assessed via an item asking, "Over the past 28 days, how many times have you exercised to "make up for" a binge-eating episode, and compulsive exercise will be assessed using the item "...how many times have you felt driven/compelled to exercise?" EDE-Q items are averages to calculate a total score ranging from 0-6, with higher scores indicating higher levels of eating pathology.
Baseline and post-intervention (week 12)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Weight bias internalization
Time Frame: baseline and post-intervention (week 12)
Internalized weight stigma will be measured using the Weight Bias Internalization Scale (WBIS). The WBIS comprises 11 items measuring self-directed weight bias and has shown excellent convergent and divergent validity within the population of interest. The WBIS items are averaged to yield a total score ranging from 1-7, with higher scores reflecting higher internalized weight bias.
baseline and post-intervention (week 12)
intervention acceptability
Time Frame: post-intervention (week 12)
Participants will complete qualitative interviews at post-treatment to provide feedback on group format, acceptability, utility, etc. Qualitative analysis of these interview transcripts will elucidate themes related to group acceptability.
post-intervention (week 12)
intervention feasibility
Time Frame: post-intervention (week 12)
Feasibility will be measured via group attendance rates across the 12 sessions.
post-intervention (week 12)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Dartmouth-Hitchcock Medical Center

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Jessica Salwen-Deremer, PhD, Dartmouth Health
  • Principal Investigator: Elizabeth Lampe, PhD, Dartmouth Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 16, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 30, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 13, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 5, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 16, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 15, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • STUDY02003218

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD may be shared to facilitate future research study recruitment and/or to answer future research questions. There is no plan to share IPD at this time.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings